Key Takeaways:
Roche is set to enter the multiple sclerosis diagnostic market with its newly CE-marked Elecsys® Neurofilament Light Chain (NfL) test, a blood-based assay that could shift monitoring from costly MRI scans to routine lab work. The approval, announced on April 13, 2026, gives Roche access to the European market for a test that measures nerve injury in relapsing-remitting multiple sclerosis (RRMS) patients.
"This brings meaningful innovation to MS disease management, offering clinicians a minimally invasive way to monitor the biological damage caused by multiple sclerosis," a Roche representative said in a statement.
The Elecsys NfL test detects neurofilament light chain, a protein released into the blood during nerve cell damage. This provides a quantifiable measure of neuroinflammation, a key indicator of disease activity in MS. The test will be available in countries accepting the CE mark. Roche has not yet disclosed pricing or revenue projections for the new test.
The approval positions Roche to compete with other companies in the growing field of neuroprognostics, including Siemens Healthineers and Quanterix, which also offer NfL tests. For Roche, a dominant player in cancer diagnostics, this marks a significant expansion of its neurology portfolio and a potential new revenue stream. The company's stock (SIX: RO) was up 1.2% in pre-market trading.
The new blood test has the potential to change the standard of care for MS patients, who typically undergo periodic and expensive MRI scans to monitor disease progression. By providing a simpler, more accessible testing method, the Elecsys NfL test could enable more frequent monitoring and earlier detection of treatment response or failure.
Multiple sclerosis is a chronic autoimmune disease that affects millions of people worldwide. The market for MS diagnostics and monitoring is substantial and growing, driven by an aging population and increasing disease prevalence. Roche's entry into this market with a novel blood test is a strategic move to capture a share of this expanding segment.
The company has not yet announced plans for FDA submission in the United States.
This article is for informational purposes only and does not constitute investment advice.
